Financial Performance - Total expenses for Q3 2025 were $10.2 million, up from $4.1 million in Q3 2024, representing a 148.8% increase[4] - The net loss attributable to shareholders for Q3 2025 was $9.4 million, or $0.24 per share, compared to a net loss of $4.3 million, or $0.23 per share in Q3 2024[5] - The company reported a total comprehensive loss of $9.4 million for Q3 2025, compared to a comprehensive loss of $4.2 million in Q3 2024[9] - Total operating expenses for the nine months ended March 31, 2025, were $24.6 million, compared to $16.9 million for the same period in 2024, indicating a 45.5% increase[9] Research and Development - Research and development expenses for the quarter were $6.0 million, compared to $2.6 million in the same quarter last year, marking a 130.8% increase[4] - The company is focused on the continued development of BB-301 for the treatment of dysphagia in OPMD patients[3] - The company plans to enroll additional subjects at a higher dose of BB-301 later this year, following the successful treatment of the sixth subject in Cohort 1[3] Assets and Cash Position - As of March 31, 2025, the company had $103.6 million in cash and cash equivalents, an increase from $50.9 million as of June 30, 2024[7] - The total assets as of March 31, 2025, were $105.2 million, compared to $52.2 million as of June 30, 2024, reflecting a 101.5% increase[7] Earnings Per Share - The basic earnings per share calculation has been revised to include pre-funded warrants in the weighted number of shares outstanding for the current and comparative periods[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39267 BENITEC BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 84-462-0206 (State or other jurisdicti ...

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in stock prices for short-term investing, highlighting that while price movements can be profitable, they can also reverse quickly, leading to potential losses [1][2]. Group 1: Stock Performance - Benitec Biopharma Limited (BNTC) has shown a solid price increase of 43.2% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 22.2% in the last four weeks, suggesting that the upward trend is still intact [5]. - BNTC is currently trading at 83.4% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like BNTC that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average ...

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]

Benitec Biopharma Limited (BNTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct ...

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct ...

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject ...

Core Insights - Benitec Biopharma Inc. has reported durable and clinically significant improvements in swallowing function for subjects treated with BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) [1][3][19] - The interim clinical study results will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting the efficacy of BB-301 in reducing dysphagic symptom burden [1][2] Summary of Clinical Results - Subject 1 showed a 37% reduction in Total Pharyngeal Residue for Thin Liquid, an 18% reduction for Solid Food, and a 29% reduction for Thick Liquids, with a 41% reduction in total dysphagic symptom burden 12 months post-treatment [8][9] - Subject 2 experienced a significant reduction in pathologic sequential swallows, achieving a clinically normal swallowing profile with a 91% reduction in total dysphagic symptom burden, resulting in an SSQ score of 68 units [10][12] - Subject 3 achieved complete resolution of pathologic sequential swallows and a 68% reduction in total dysphagic symptom burden, with an SSQ score of 70 units indicative of a clinically normal swallowing profile at 3 months post-treatment [13][15] Study Design and Methodology - The study is a Phase 1b/2a, open-label, dose escalation trial assessing the safety and clinical activity of BB-301 in OPMD patients [3][19] - Key assessment methods include videofluoroscopic swallowing study (VFSS) for swallowing efficiency and effectiveness, and the Sydney Swallow Questionnaire (SSQ) for patient-reported outcomes [2][5] Company Overview - Benitec Biopharma Inc. is focused on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform, targeting chronic and life-threatening conditions like OPMD [19]